After a May report finding a third of the malaria pills inspected in Asia and Africa were counterfeit, observers piled on pharmaceutical companies in India and China as likely bad guys. But the truth is a little harder to swallow.
In the "AIDS exceptionalism" debate, emotions run high, and the options are difficult: Shift some AIDS funding to other care, or find billions in new support.